COCP - CIK 0001412486
The table below shows Cocrystal Pharma, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$2.34M | -$2.94M | -$4.50M | -$3.11M | -$3.91M | -$1.77M |
| Capital expenditure | - | - | $8.00K | $45.00K | - | $25.00K |
| Investing cash flow | - | - | -$8.00K | -$45.00K | - | -$25.00K |
| Dividends paid | - | - | - | - | - |
Cocrystal Pharma, Inc. reported operating cash flow of -$8.19M for fiscal year 2025. That is up 50.3% from -$16.48M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$14.65M (FY 2016) to -$8.19M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | - | - | - | -$7.00K | -$6.00K | $2.06M |